Investigating how GPR56 affects kidney cell injury in early diabetes-related kidney disease
Official title: Role of GPR56 in glomerular endothelial cell injury in early diabetic kidney disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-11013319 · Data updated 2026-11-12
This study is looking at how a specific protein called GPR56 affects kidney cells during the early stages of diabetic kidney disease, with the hope of finding new ways to help people with this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2021 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $138,974 |
| NIH project number | 5K01DK125614-05 |
| Project ID | NIH-11013319 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage diabetic kidney disease.
✕Less likely to help
Patients with advanced diabetic kidney disease or those without diabetes are unlikely to benefit from this research.
What this research studies
This research focuses on understanding the role of GPR56, a specific receptor, in the injury of glomerular endothelial cells (GECs) during the early stages of diabetic kidney disease (DKD). By isolating GECs from genetically modified mice, researchers will analyze the differences in gene expression between diabetic and non-diabetic cells using advanced techniques like RNA sequencing. The goal is to uncover the mechanisms behind GEC dysfunction, which could lead to early therapeutic interventions for patients with DKD.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of diabetic kidney disease.
How similar studies have gone: Previous research has shown promising results in understanding endothelial cell dysfunction in diabetic conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Fu, Jia — Icahn School of Medicine at Mount Sinai
- Study coordinator: Fu, Jia
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.